Skip to Content

George R. Blumenschein, Jr., MD

Present Title & Affiliation

Primary Appointment

Professor, Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Dr. George R. Blumenschein, Jr is an Associate Professor of Medicine in Department of Thoracic/Head & Neck Medical Oncology at The University of Texas MD Anderson Cancer Center in Houston, Texas. He received his B.A. from Vanderbilt University and his M.D. degree from University of Texas Medical School in Houston. He completed his residency in internal medicine at The University of Texas Health Science Center in Houston and his fellowship training in medical oncology at The University of Texas MD Anderson Cancer Center. He joined The University of Texas MD Anderson Cancer Center in 2000 as an Instructor of Medicine. He was promoted to Assistant Professor of Medicine in 2001. He is board certified in both internal medicine and medical oncology. Dr. Blumenschein is a member of ASCO, SWOG, RTOG, and AACR. He has authored or co-authored papers and book chapters regarding the management of lung and head and neck cancers. Dr Blumenschein’s area of focus is in new drug development and multimodality therapy for the treatment of lung and head and neck cancers. Specifically, he is interested in the utilization of compounds with novel mechanisms of action in clinical trials for the treatment of these tumors. He serves as the principle investigator on a number of research protocols.

Office Address

The University of Texas MD Anderson Cancer Center
1515 Holcombe Blvd.
Unit Number: 432
Houston, TX 77030
Room Number: FC9.2012
Phone: (713) 792-6363
Fax: (713) 792-1220

Education & Training

Degree-Granting Education

1994 The University of Texas Health Science Center at Houston, Houston, TX, MD, Medicine
1987 Vanderbilt University, Nashville, TN, BA, Political Science

Postgraduate Training

7/1997-7/2000 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
6/1994-6/1997 Clinical Residency, Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX


Other Appointments/Responsibilities

Principal Investigator/Expert Advisor, Bristol Myers Squibb Immuno-Collaborative Institute (IOCI), Houston, TX, 4/2013-present

Institutional Committee Activities

Member, Tenure Issues Committee, 2011-present
Member, Research Affairs Committee, 2011-present

Honors and Awards

2000 Scholarship to Methods in Clinical Cancer Research Workshop, ASCO/AACR

Selected Publications

Peer-Reviewed Original Research Articles

1. Jakob JA, Kies MS, Glisson BS, Kupferman ME, Liu DD, Lee JJ, El-Naggar AK, Gonzalez-Angulo AM, Blumenschein GR. A Phase II study of Gefitinib in Patients with Advanced Salivary Gland Cancers. Head Neck 37(5):644-649, 5/2015. e-Pub 3/2015. PMID: 24585506.
2. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget 5(19):8937-8946, 10/2014. PMID: 25313136.
3. Komaki R, Paulus R, Blumenschein GR, Curran WJ, Robert F, Thariat J, Werner-Wasik M, Choy H, Hirsch FR, Ang KK. EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324. Radiother Oncol 112(1):30-6, 7/2014. e-Pub 7/2014. PMCID: PMC4169722.
4. Spigel DR, Ervin TJ, Ramlau RA, Daniel DB, Goldschmidt JH, Blumenschein GR, Krzakowski MJ, Robinet G, Godbert B, Barlesi F, Govindan R, Patel T, Orlov SV, Wertheim MS, Yu W, Zha J, Yauch RL, Patel PH, Phan SC, Peterson AC. Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 31(32):4105-14, 11/2013. e-Pub 10/2013. PMID: 24101053.
5. Parinyanitikul N, Blumenschein GR, Wu Y, Lei X, Chavez-Macgregor M, Smart M, Gonzalez-Angulo AM. Mesothelin expression and survival outcomes in triple receptor negative breast cancer. Clin Breast Cancer 13(5):378-384, 10/2013. e-Pub 6/2013. PMCID: PMC3839051.
6. Groen HJ, Socinski MA, Grossi F, Juhasz E, Gridelli C, Baas P, Butts CA, Chmielowska E, Usari T, Selaru P, Harmon C, Williams JA, Gao F, Tye L, Chao RC, Blumenschein GR. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small cell lung cancer (NSCLC). Ann Oncol 24(9):2382-9, 9/2013. e-Pub 6/2013. PMID: 23788751.
7. Gonzalez-Angulo AM, Blumenschein GR. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev 39(4):313-20, 6/2013. e-Pub 12/2012. PMCID: PMC3604032.
8. Tam AL, Kim ES, Lee JJ, Ensor JE, Hicks ME, Tang X, Blumenschein GR, Alden CM, Erasmus JJ, Tsao A, Lippman SM, Hong WK, Wistuba II, Gupta S. Feasibility of Image-Guided Transthoracic Core Needle Biopsy in the BATTLE Lung Trial. J Thorac Oncol 8(4):436-42, 4/2013. PMCID: PMC3879952.
9. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for non-small cell lung cancer--novel approaches to improve patient outcome. Zhongguo Fei Ai Za Zhi 16(4):C9-20, 4/2013. PMID: 23601304.
10. Argiris A, Kotsakis AP, Hoang T, Worden FP, Savvides P, Gibson MK, Gyanchandani R, Blumenschein GR, Chen HX, Grandis JR, Harari PM, Kies MS, Kim S. Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 24(1):220-5, 1/2013. e-Pub 8/2012. PMCID: PMC3525135.
11. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-MacGregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein GR. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer 119(1):7-15, 1/2013. e-Pub 6/2012. PMCID: PMC3461089.
12. Tsao AS, Liu S, Lee JJ, Alden C, Blumenschein G, Herbst R, Davis SE, Kim E, Lippman S, Stewart D, Tang XM, Wistuba I, Hong WK. Clinical outcomes and biomarker profiles of elderly pre-treated NSCLC patients from the BATTLE trial. J Thorac Oncol 7(11):1645-52, 11/2012. PMID: 23059780.
13. Kies MS, Boatright DH, Li G, Blumenschein G, El-Naggar AK, Brandon Gunn G, Lewin JS, Steinhaus GD, Sturgis EM. Phase II trial of induction chemotherapy followed by surgery for squamous cell carcinoma of the oral tongue in young adults. Head Neck 34(9):1255-62, 9/2012. e-Pub 10/2011. PMID: 22009800.
14. Blumenschein GR, Ciuleanu T, Robert F, Groen HJ, Usari T, Ruiz-Garcia A, Tye L, Chao RC, Juhasz E. Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: a lead-in study. J Thorac Oncol 7(9):1406-16, 9/2012. PMID: 22743295.
15. Blumenschein GR, Mills GB, Gonzalez-Angulo AM. Targeting the hepatocyte growth factor-cMET axis in cancer therapy. J Clin Oncol 30(26):3287-96, 9/2012. e-Pub 8/2012. PMCID: PMC3434988.
16. Belani CP, Goss G, Blumenschein G. Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treat Rev 38(3):173-84, 5/2012. e-Pub 6/2011. PMID: 21715100.
17. Shepherd FA, Douillard JY, Blumenschein GR. Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome. J Thorac Oncol 6(10):1763-1773, 10/2011. e-Pub 9/2011. PMID: 21876456.
18. Heath EI, Blumenschein GR, Cohen RB, Lorusso PM, Loconte NK, Kim ST, Ruiz-Garcia A, Chao RC, Wilding G. Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemother Pharmacol 68(3):703-12, 9/2011. e-Pub 12/2010. PMCID: PMC3400085.
19. Adjei AA, Blumenschein GR, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clin Lung Cancer 12(4):212-7, 7/2011. e-Pub 4/2011. PMID: 21726819.
20. Tran HT, Zinner RG, Blumenschein GR, Oh YW, Papadimitrakopoulou VA, Kim ES, Lu C, Malik M, Lum BL, Herbst RS. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC). Invest New Drugs 29(3):499-505, 6/2011. e-Pub 1/2010. PMID: 20094773.
21. Blumenschein GR, Paulus R, Curran WJ, Robert F, Fossella F, Werner-Wasik M, Herbst RS, Doescher PO, Choy H, Komaki R. Phase II Study of Cetuximab in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small-Cell Lung Cancer: RTOG 0324. J Clin Oncol 29(17):2312-8, 6/2011. e-Pub 5/2011. PMCID: PMC3107747.
22. Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR, Tsao A, Stewart DJ, Hicks ME, Erasmus J, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK. The BATTLE Trial: Personalizing Therapy for Lung Cancer. Cancer Discov 1(1):44-53, 6/2011. e-Pub 6/2011. PMID: 22586319.
23. Blumenschein GR, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT, Lakshmaiah K, Reckamp K, Hei YJ, Kracht K, Sun YN, Sikorski R, Schwartzberg L, on behalf of the Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. e-Pub 2/2011. PMID: 21321086.
24. Johnson FM, Bekele BN, Feng L, Wistuba I, Tang XM, Tran HT, Erasmus JJ, Hwang LL, Takebe N, Blumenschein GR, Lippman SM, Stewart DJ. Phase II Study of Dasatinib in Patients With Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 28(30):4609-15, 10/2010. e-Pub 9/2010. PMCID: PMC2974341.
25. William WN, Uyeki J, Johnson FM, Feng L, Peeples BO, Fossella FV, Karp DD, Blumenschein GR, Stewart DJ, Glisson BS. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma. Cancer 116(10):2409-15, 5/2010. e-Pub 3/2010. PMID: 20225329.
26. Ross HJ, Blumenschein GR, Aisner J, Damjanov N, Dowlati A, Garst J, Rigas JR, Smylie M, Hassani H, Allen KE, Leopold L, Zaks TZ, Shepherd FA. Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non-Small Cell Lung Cancer. Clin Cancer Res 16(6):1938-49, 3/2010. e-Pub 3/2010. PMID: 20215545.
27. Blumenschein GR, Reckamp K, Stephenson GJ, O'Rourke T, Gladish G, McGreivy J, Sun YN, Ye Y, Parson M, Sandler A. Phase 1b study of motesanib, an oral angiogenesis inhibitor, in combination with carboplatin/paclitaxel and/or panitumumab for the treatment of advanced non-small cell lung cancer. Clin Cancer Res 16(1):279-90, 1/2010. e-Pub 12/2009. PMID: 20028752.
28. Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O'Leary J, Reck M. Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer. J Clin Oncol 27(26):4274-80, 9/2009. e-Pub 8/2009. PMID: 19652055.
29. Phan R, Phan L, Ginsberg LE, Blumenschein G, Williams MD, Esmaeli B. Durable response to chemotherapy for recurrent squamous cell carcinoma of the cheek with perineural spread. Arch Ophthalmol 127(8):1074-5, 8/2009. PMID: 19667357.
30. Lynch TJ, Blumenschein GR, Engelman JA, Espinoza-Delgado I, Govindan R, Hanke J, Hanna NH, Heymach JV, Hirsch FR, Janne PA, Lilenbaum RC, Natale RB, Riely GJ, Sequist LV, Shapiro GI, Shaw A, Shepherd FA, Socinski M, Sorensen AG, Wakelee HA, Weitzman A. Summary statement novel agents in the treatment of lung cancer: Fifth cambridge Conference opportunities for combination therapy. J Thorac Oncol 3((6 Suppl 2)):S107-12, 6/2008. PMID: 18520291.
31. Blumenschein GR, Khuri FR, von Pawel J, Gatzemeier U, Miller WH, Jotte RM, Le Treut J, Sun SL, Zhang JK, Dziewanowska ZE, Negro-Vilar A. A Randomized Phase III Trial Comparing Bexarotene (L1069-48) /Carboplatin/Paclitaxel versus Carboplatin/Paclitaxel in Chemotherapy-Naïve Patients with Advanced or Metastatic Non-Small Cell Lung Cancer (SPIRIT II). J Clin Oncol 26(11):1879-85, 4/2008. PMID: 18398153.
32. Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR, Onn A. Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. J Thorac Oncol 3(4):351-7, 4/2008. PMID: 18379352.
33. Husain A, Blumenschein G, Esmaeli B. Treatment and Outcomes for Metastatic Sebaceous Cell Carcinoma of the Eyelid. Int J Dermatol 47(3):276-9, 3/2008. PMID: 18289332.
34. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ, Ricker JL, Chiao JH, Chen C, Frankel SR. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Invest New Drugs 26(1):81-7, 2/2008. e-Pub 10/2007. PMID: 17960324.
35. Williams MD, Roberts D, Blumenschein GR, Temam S, Kies MS, Rosenthal DI, Weber RS, El-Naggar AK. Differential expression of hormonal and growth factor receptors in salivary duct carcinomas: biologic significance and potential role in therapeutic stratification of patients. Am J Surg Pathol 31(11):1645-52, 11/2007. PMID: 18059220.
36. Huang EH, Liao Z, Cox JD, Guerrero TM, Chang JY, Jeter M, Borghero Y, Wei X, Fossella F, Herbst RS, Blumenschein GR, Moran C, Allen PK, Komaki R. Comparison of outcomes for patients with unresectable, locally advanced non-small-cell lung cancer treated with induction chemotherapy followed by concurrent chemoradiation vs. concurrent chemoradiation alone. Int J Radiat Oncol Biol Phys 68(3):779-85, 7/2007. e-Pub 4/2007. PMID: 17418967.
37. Heymach JV, Nilsson M, Blumenschein G, Papadimitrakopoulou V, Herbst R. Epidermal growth factor receptor inhibitors in development for the treatment of non-small cell lung cancer. Clin Cancer Res 12(14 Pt 2):4441s-4445s, 7/2006. PMID: 16857825.
38. Thomas SK, Fossella FV, Liu D, Schaerer R, Tsao AS, Kies MS, Pisters KM, Blumenschein GR, Jr, Glisson BS, Lee JJ, Herbst RS, Zinner RG. Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program. Clin Lung Cancer 7(5):326-31, 3/2006. PMID: 16640804.
39. Lu C, Spitz MR, Zhao H, Dong Q, Truong M, Chang JY, Blumenschein GR, Jr, Hong WK, Wu X. Association between glutathione S-transferase pi polymorphisms and survival in patients with advanced nonsmall cell lung carcinoma. Cancer 106(2):441-7, 1/2006. PMID: 16342067.

Invited Articles

1. Blumenschein GR. Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC). Invest New Drugs 30(4):1802-11, 8/2012. e-Pub 10/2011. PMID: 21987350.
2. Raghav KP, Blumenschein GR. Motesanib and advanced NSCLC: experiences and expectations. Expert Opin Investig Drugs 20(6):859-69, 6/2011. e-Pub 5/2011. PMID: 21534718.
3. Blumenschein G. Sorafenib in lung cancer: clinical developments and future directions. J Thorac Oncol 3((6 Suppl 2)):S124-7, 6/2008. PMID: 18520294.
4. Blumenschein G Jr., Heymach, JV. Angiogenesis Inhibitors for lung Cancer: Clinical developments and future directions. J Thorac Oncol 1(7)(7):744-748, 2006. PMID: 17409952.


1. Tsao AS1, Liu S, Lee JJ, Alden CM, Blumenschein GR Jr, Herbst R, Davis SE, Kim E, Lippman S, Heymach J, Tran H, Tang X, Wistuba I, Hong WK. Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial. Journal of Thoracic Oncology 8(5):658-661, 5/2013.
2. Byers LA1, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clinical Cancer Research 19(1):279-290, 1, 1/2013.

Last updated: 6/18/2015